.
NON-RECEPTOR TYROSINE KINASE INHIBITORS
1. Bcr-Abl1 Inhibitors
2. JAK Inhibitors
3. BTK Inhibitors
Check Also
KINASE INHIBITORS - An Overview
RECEPTOR TYROSINE KINASE INHIBITORS
3. EGFR Inhibitors
4. FLT3 Inhibitors
5. VEGFR/FGFR/PDGFR Inhibitors
6. TRK Inhibitors
SERINE / THEONINE KINASE INHIBITORS
1. BRAF/MEK/ERK Inhibitors
2. CDK Inhibitors
3. PI3K/AKT/mTOR Inhibitors
- Kinase Inhibitors – An Overview
- Approved Oncology Targeting Kinase Inhibitors. (86 Molecules)
- Approved Non-Oncology Targeting Kinase Inhibitors. (16 Molecules)
- Kinase Inhibitors in Active Clinical Development – Developers, Pipeline, Target & Cancer Indication. (330 Molecules)
- Kinase Inhibitors in Active Preclinical Development – Developers, Pipeline, Target & Cancer Indication. (244 Molecules)
- Clinical Stage Companies Developing Oncology Targeting Kinase Inhibitors. (227 Companies)
- Preclinical / Early Stage Companies Developing Oncology Targeting Kinase Inhibitors. (122 Companies)